What can the genome tell us about LDL cholesterol?

The Lancet

Volumn 371, Issue 9611, 2008, Pages 450-452

  Krauss, Ronald M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN E1; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CHROMOSOME 1P; CHROMOSOME 1P13.3; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE CLUSTER; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENOME; HEART INFARCTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 38849187888     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60213-5     Document Type: Note

References (16)

1. Dammerman M., and Breslow J. Genetic basis of lipoprotein disorders. Circulation 91 (1995) 505-512
2. Cohen J., Boerwinkle E., Mosley Jr. T., and Hobbs H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
3. Pollex R., and Hegele R. Genetic determinants of plasma lipoproteins. Nat Clin Pract Cardiovasc Med 4 (2007) 600-609
4. Mitchell B., Kammerer C., Blangero J., et al. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans: the San Antonio Family Heart Study. Circulation 94 (1996) 2159-2170
5. Pilia G., Chen W., Scuteri A., et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet 2 (2006) e132
6. Willer C., Sanna S., Jackson A., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40 (2008) 161-169
7. Kathiresan S., Melander O., Guiducci C., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40 (2008) 189-197
8. Sandhu M., Waterworth D., Debenham S., et al. LDL-cholesterol concentrations: a genome-wide association study. Lancet 371 (2008) 483-491
9. Samani N., Erdmann J., Hall A., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007) 443-453
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
11. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
12. Tauris J., Ellgaard L., Jacobsen C., et al. The carboxy-terminal domain of the receptor-associated protein binds to the Vps10p domain of sortilin. FEBS Lett 429 (1998) 27-30
13. British Heart Foundation. Low density lipoprotein receptor (March 12, 2007). http://www.ucl.ac.uk/ldlr/Current/index.php?select_db=LDLR (accessed Jan 29, 2008).
14. Krauss RM, Mangravite LM, Smith JD, et al. Variation in the HMG-CoA reductase gene is associated with racial differences in LDL-cholesterol response to simvastatin treatment. Circulation (in press).
15. Ordovas J., Corella D., and Kaput J. Nutrient-gene interactions in lipoprotein metabolism-an overview. Forum Nutr 60 (2007) 102-109
16. Berneis K., and Krauss R. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379